The Experts below are selected from a list of 249 Experts worldwide ranked by ideXlab platform
Robin Demuth - One of the best experts on this subject based on the ideXlab platform.
-
Premenstrual Syndrome and Premenstrual dysphoric disorder
American Family Physician, 2011Co-Authors: Wendy S Biggs, Robin DemuthAbstract:Premenstrual Syndrome is defined as recurrent moderate psychological and physical symptoms that occur during the luteal phase of menses and resolve with menstruation. It affects 20 to 32 percent of premenopausal women. Women with Premenstrual dysphoric disorder experience affective or somatic symptoms that cause severe dysfunction in social or occupational realms. The disorder affects 3 to 8 percent of premenopausal women. Proposed etiologies include increased sensitivity to normal cycling levels of estrogen and progesterone, increased aldosterone and plasma renin activity, and neurotransmitter abnormalities, particularly serotonin. The Daily Record of Severity of Problems is one tool with which women may self-report the presence and severity of Premenstrual symptoms that correlate with the criteria for Premenstrual dysphoric disorder in the Diagnostic and Statistical Manual of Mental Disorders, 4th ed., text revision. Symptom relief is the goal for treatment of Premenstrual Syndrome and Premenstrual dysphoric disorder. There is limited evidence to support the use of calcium, vitamin D, and vitamin B6 supplementation, and insufficient evidence to support cognitive behavior therapy. Serotonergic antidepressants (citalopram, escitalopram, fluoxetine, sertraline, venlafaxine) are first-line pharmacologic therapy.
Seth Bodden - One of the best experts on this subject based on the ideXlab platform.
-
Premenstrual Syndrome and Premenstrual dysphoric disorder
American Family Physician, 2016Co-Authors: Sabrina Hofmeister, Seth BoddenAbstract:Premenstrual disorders affect up to 12% of women. The subspecialties of psychiatry and gynecology have developed overlapping but distinct diagnoses that qualify as a Premenstrual disorder; these include Premenstrual Syndrome and Premenstrual dysphoric disorder. These conditions encompass psychological and physical symptoms that cause significant impairment during the luteal phase of the menstrual cycle, but resolve shortly after menstruation. Patientdirected prospective recording of symptoms is helpful to establish the cyclical nature of symptoms that differentiate Premenstrual Syndrome and Premenstrual dysphoric disorder from other psychiatric and physical disorders. Physicians should tailor therapy to achieve the greatest functional improvement possible for their patients. Select serotonergic antidepressants are first-line treatments. They can be used continuously or only during the luteal phase. Oral contraceptives and calcium supplements may also be used. There is insufficient evidence to recommend treatment with vitamin D, herbal remedies, or acupuncture, but there are data to suggest benefit from cognitive behavior therapy.
Shaugn O'brien - One of the best experts on this subject based on the ideXlab platform.
-
Prescribing patterns in Premenstrual Syndrome.
BMC women's health, 2002Co-Authors: Katrina Wyatt, Paul W Dimmock, Martin Frischer, Paul W Jones, Shaugn O'brienAbstract:Over 300 therapies have been proposed for Premenstrual Syndrome. To date there has been only one survey conducted in the UK of PMS treatments prescribed by GPs, a questionnaire-based study by the National Association of Premenstrual Syndrome in 1989. Since then, selective serotonin re-uptake inhibitors have been licensed for severe PMS/PMDD, and governmental recommendations to reduce the dosage of vitamin B6 (the first choice over-the-counter treatment for many women with PMS) have been made. This study investigates the annual rates of diagnoses and prescribing patterns for Premenstrual Syndrome (1993–1998) within a computerised general practitioner database. Retrospective survey of prescribing data for Premenstrual Syndrome between 1993–1998 using the General Practice Research Database for the West Midlands Region which contains information on 282,600 female patients Overall the proportion of women with a prescription-linked diagnosis of Premenstrual Syndrome has halved over the five years. Progestogens including progesterone were the most commonly recorded treatment for Premenstrual Syndrome during the whole study period accounting for over 40% of all prescriptions. Selective serotonin-reuptake inhibitors accounted for only 2% of the prescriptions in 1993 but rose to over 16% by 1998, becoming the second most commonly recorded treatment. Vitamin B6 accounted for 22% of the prescriptions in 1993 but dropped markedly between 1997 and 1998 to 11%. This study shows a yearly decrease in the number of prescriptions linked to diagnoses for Premenstrual Syndrome. Progestogens including progesterone, is the most widely prescribed treatment for Premenstrual Syndrome despite the lack of evidence demonstrating their efficacy.
Elizabeth R Bertonejohnson - One of the best experts on this subject based on the ideXlab platform.
-
recreational physical activity and Premenstrual Syndrome in young adult women a cross sectional study
PLOS ONE, 2017Co-Authors: Aimee R Krolldesrosiers, Alayne G Ronnenberg, Sofija E Zagarins, Serena C Houghton, Biki B Takashimauebelhoer, Elizabeth R BertonejohnsonAbstract:Introduction It is estimated that up to 75% of premenopausal women experience at least one Premenstrual symptom and 8–20% meet clinical criteria for Premenstrual Syndrome. Premenstrual Syndrome substantially reduces quality of life for many women of reproductive age, with pharmaceutical treatments having limited efficacy and substantial side effects. Physical activity has been recommended as a method of reducing menstrual symptom severity. However, this recommendation is based on relatively little evidence, and the relationship between physical activity, Premenstrual symptoms, and Premenstrual Syndrome remains unclear. Methods We evaluated the relationship between physical activity and Premenstrual Syndrome and Premenstrual symptoms among 414 women aged 18–31. Usual Premenstrual symptom experience was assessed with a modified version of the Calendar of Premenstrual Experiences. Total, physical, and affective Premenstrual symptom scores were calculated for all participants. Eighty women met criteria for moderate-to-severe Premenstrual Syndrome, while 89 met control criteria. Physical activity, along with dietary and lifestyle factors, was assessed by self-report. Results Physical activity was not significantly associated with total, affective, or physical Premenstrual symptom score. Compared to the women with the lowest activity, women in tertiles 2 and 3 of activity, classified as metabolic equivalent task hours, had prevalence odds ratios for Premenstrual Syndrome of 1.5 (95% CI: 0.6–3.7) and 0.9 (95% CI: 0.4–2.4), respectively (p-value for trend = 0.85). Conclusions We found no association between physical activity and either Premenstrual symptom scores or the prevalence of Premenstrual Syndrome.
Wendy S Biggs - One of the best experts on this subject based on the ideXlab platform.
-
Premenstrual Syndrome and Premenstrual dysphoric disorder
American Family Physician, 2011Co-Authors: Wendy S Biggs, Robin DemuthAbstract:Premenstrual Syndrome is defined as recurrent moderate psychological and physical symptoms that occur during the luteal phase of menses and resolve with menstruation. It affects 20 to 32 percent of premenopausal women. Women with Premenstrual dysphoric disorder experience affective or somatic symptoms that cause severe dysfunction in social or occupational realms. The disorder affects 3 to 8 percent of premenopausal women. Proposed etiologies include increased sensitivity to normal cycling levels of estrogen and progesterone, increased aldosterone and plasma renin activity, and neurotransmitter abnormalities, particularly serotonin. The Daily Record of Severity of Problems is one tool with which women may self-report the presence and severity of Premenstrual symptoms that correlate with the criteria for Premenstrual dysphoric disorder in the Diagnostic and Statistical Manual of Mental Disorders, 4th ed., text revision. Symptom relief is the goal for treatment of Premenstrual Syndrome and Premenstrual dysphoric disorder. There is limited evidence to support the use of calcium, vitamin D, and vitamin B6 supplementation, and insufficient evidence to support cognitive behavior therapy. Serotonergic antidepressants (citalopram, escitalopram, fluoxetine, sertraline, venlafaxine) are first-line pharmacologic therapy.